Jaime Castro, MD
Endocrinology · Fort Worth, TXNPI 1932159951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 367 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Abbott$1K
- AbbVie$623
- Amgen$614
- Medtronic$610
- Novo Nordisk$523
- plus $3K from 34 others
Across 1 payment — averaging $126.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$126
What the payments were for
- Food & beverage$7,63299%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 58 | $1,312 |
| Abbott | 46 | $1,067 |
| AbbVie | 44 | $623 |
| Amgen(2 entities) | 34 | $614 |
| Medtronic(2 entities) | 22 | $610 |
| Novo Nordisk | 22 | $523 |
| Sanofi-aventis U.S. LLC | 15 | $386 |
| Xeris Pharmaceuticals, Inc. | 17 | $321 |
| AstraZeneca | 12 | $213 |
| Dexcom, Inc. | 8 | $171 |
| Chiesi USA, Inc. | 5 | $168 |
| Pfizer | 8 | $160 |
| Tandem Diabetes Care, Inc. | 6 | $111 |
| Insulet Corporation | 5 | $108 |
| Merck | 7 | $101 |
| Zealand Pharma US, Inc. | 6 | $101 |
| Corcept Therapeutics | 6 | $98 |
| Medicure Pharma Inc. | 1 | $95 |
| Madrigal Pharmaceuticals | 4 | $94 |
| Bayer | 5 | $91 |
| IBSA Pharma Inc. | 5 | $81 |
| Novartis | 3 | $59 |
| Shire North American Group Inc | 3 | $51 |
| Globus Medical | 2 | $50 |
| Recordati_rare_diseases_inc. | 2 | $49 |
| Johnson & Johnson | 3 | $48 |
| GSK | 2 | $48 |
| Sequel Med Tech, LLC | 2 | $46 |
| Mannkind Corporation | 2 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| Nevro Corp. | 1 | $35 |
| Intra-sana Laboratories | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $21 |
| Roche Diabetes Care, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Optos, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$375
- Minimed 670G System$247
- MOUNJARO$125
- Repatha$109
How this compares
Too few endocrinology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $218,388 |
| TrulicityDulaglutide | 89 | $141,258 |
| JardianceEmpagliflozin | 106 | $123,849 |
| RybelsusSemaglutide | 60 | $109,016 |
| MounjaroTirzepatide | 27 | $56,906 |
| TradjentaLinagliptin | 57 | $49,507 |
| JanuviaSitagliptin Phosphate | 45 | $47,117 |
| FarxigaDapagliflozin Propanediol | 48 | $41,208 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $39,969 |
| Humalog Kwikpen U-100Insulin Lispro | 79 | $39,809 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $39,358 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $31,571 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $31,121 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 149 | $24,796 |
| HumalogInsulin Lispro | 72 | $20,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Levemir | $523 | $348,008254 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $1,312 | $223,999213 claims |
| Boehringer IngelheimJardiance, Tradjenta | $40 | $173,356163 claims |
| MerckJanuvia | $101 | $47,11745 claims |
| AstraZenecaFarxiga | $213 | $41,20848 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $386 | $22,33747 claims |
| AbbVieSynthroid | $623 | $10,76495 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Texason file to place this against a meaningful peer group, so we don't.
Other endocrinology in Fort Worth
- Israel HartmanArlington$520K
- Donald GardnerHouston$13K
- David FeinsteinDallas$10K
- Basma AtaallahHouston$950
- Eric DealHouston$0
- Uma GunasekaranDallas$0
- Ananya JhaveriDallas$0
- Leili RahimiDallas$0
- Anwar MoryanDenton$0
- Scott CarlsonHouston$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.